Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Earnings Data
Report Date
Mar 25, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.52Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the clinical development of Daramycin and operational readiness for commercialization. However, financial challenges were evident with zero revenue in 2025 and increased operating expenses, alongside the need to address regulatory hurdles following a CRL.Company Guidance
HOPE-3 Phase 3 Clinical Study
The upcoming top-line readout from the HOPE-3 Phase 3 clinical study of Daramycin, aimed at treating Duchenne muscular dystrophy, represents a significant milestone. The trial is one of the largest double-blind, placebo-controlled studies in the Duchenne population, enrolling 105 participants across 20 centers in the US.
Strong Safety Profile
Daramycin has demonstrated a strong and consistent safety profile across more than 800 infusions for approximately 150 boys and young men with Duchenne, with no new or emerging safety signals observed.
CMC Achievements
The San Diego commercial facility is fully operational and preparing for GMP production, with all CMC-related items cited in the CRL addressed. This ensures readiness for commercialization and long-term product consistency.
Potential Approval and Non-dilutive Capital Opportunities
If Daramycin is approved, Capricor is eligible for an $80 million milestone payment from NS Pharma and a priority review voucher.
Exosome Platform Development
The StealthX program under Project NextGen is advancing, with a Phase 1 clinical trial evaluating a next-generation COVID-19 vaccine. Positive results could lead to strategic collaborations and highlight the platform's potential.
CAPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CAPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $5.56 | $6.20 | +11.51% |
Aug 11, 2025 | $7.82 | $8.04 | +2.81% |
May 13, 2025 | $7.30 | $7.67 | +5.07% |
Mar 19, 2025 | $12.22 | $14.36 | +17.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Capricor Therapeutics (CAPR) report earnings?
Capricor Therapeutics (CAPR) is schdueled to report earning on Mar 25, 2026, After Close (Confirmed).
What is Capricor Therapeutics (CAPR) earnings time?
Capricor Therapeutics (CAPR) earnings time is at Mar 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CAPR EPS forecast?
CAPR EPS forecast for the fiscal quarter 2025 (Q4) is -0.52.